Loading…
Loading…
AL amyloidosis is a plasma cell disorder in which abnormal light chains deposit in organs and impair their function.
Quick Answer
AL amyloidosis is a plasma cell disorder in which abnormal light chains deposit in organs and impair their function. Dr. Sachita Baniya (NMC 20158, 8+ years of clinical experience in haematology and haemato-oncology) evaluates al amyloidosis at Kathmandu Neurology Clinic & Cognitive Center, 117 Lal Durbar Marg, Kathmandu, Bagmati Province 44600, Nepal — evidence-based, medically reviewed.
AL amyloidosis can affect the heart, kidneys, liver, nerves and gut. Diagnosis requires tissue confirmation and identification of the plasma cell clone. Treatment aims to suppress the clone and preserve organ function.
Diagnosis requires tissue biopsy with Congo red staining and amyloid typing, plus serum and urine protein studies, free light chains and bone marrow assessment. Cardiac and renal staging guide treatment.
Treatment targets the plasma cell clone with regimens adapted to organ function. Cardiac and renal supportive care is essential. Autologous transplant is considered in selected fit patients. Response is monitored with free light chains and organ measures.
Management is individualized and discussed with benefits, limitations, and follow-up.
There is no proven prevention. Early recognition of unexplained heart, kidney or nerve symptoms is important.
Red flags — seek urgent care
It is a disorder in which abnormal antibody light chains form amyloid deposits in organs. It is related to plasma cell disorders such as myeloma and MGUS.
Treatment can suppress the plasma cell clone and stabilise or improve organ function, but advanced organ damage may not be reversible. Early diagnosis improves options.
Tissue biopsy with Congo red staining and typing is required, along with blood and urine protein studies, free light chains and bone marrow assessment.
Cardiac amyloidosis can cause heart failure, arrhythmia and sudden death. Cardiac assessment and careful fluid management are central to care.
Yes. It can cause proteinuria and kidney failure. Monitoring urine protein and kidney function is part of follow-up.
Autologous transplant is considered in selected fit patients with controlled disease. Eligibility is individualised.
AL is caused by light chain deposition from a plasma cell clone. ATTR is caused by transthyretin and is managed differently. Typing is essential.
Regular blood and urine protein studies, free light chains, cardiac and renal assessment, and monitoring for treatment toxicity.
Specialist assessment for abnormal blood counts, anaemia, low platelets, bleeding, clotting and suspected blood disorders.
Diagnosis and treatment of multiple myeloma, MGUS, smouldering myeloma and AL amyloidosis.
Immunophenotyping for leukemia, lymphoma, plasma cell disorders and cytopenias.
Multiple myeloma is a cancer of plasma cells that causes bone disease, anaemia, kidney problems and immune suppression.
MGUS is a common precursor plasma cell condition with a small monoclonal protein and no organ damage.
Smouldering myeloma meets laboratory criteria for myeloma but has no organ damage or myeloma-defining events.
Content on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.
Reviewed by Dr. Jitendra Prasad Yadav • Last reviewed: 2026-11-10
Content is educational and aligns with standard medical references; individual evaluation may vary. External links provide context and do not imply endorsement.
Doctor — medically reviewed
Dr. Sachita Baniya
Consultant Haemato-Oncologist & Clinical Hematologist • MBBS, FCPS (Clinical Haematology) • NMC 20158
This condition guide was medically reviewed by Dr. Sachita Baniya.
On this site
Article information
Emergency
For sudden neurologic change, thunderclap headache, or seizure >5 min, seek emergency services now.